- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.08. | BioNexus Gene Lab Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 30.07. | BioNexus Gene Lab Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 30.07. | BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance-Touted as a new "DeepSeek Moment" in Precision Oncology | 13 | GlobeNewswire (USA) | ||
| 01.07. | BioNexus Gene Lab Stock Soars 239% | 15 | RTTNews | ||
| 23.06. | BioNexus Gene Lab Corp - 8-K, Current Report | 10 | SEC Filings | ||
| 30.04. | BioNexus Gene Lab erlangt NASDAQ-Konformität wieder | 9 | Investing.com Deutsch | ||
| 30.04. | BioNexus Gene Lab regains Nasdaq compliance | 1 | Investing.com | ||
| 30.04. | BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness | 195 | GlobeNewswire (Europe) | KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today... ► Artikel lesen | |
| BIONEXUS GENE LAB Aktie jetzt für 0€ handeln | |||||
| 30.04. | BioNexus Gene Lab Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 29.04. | BioNexus Gene Lab Corp - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 15.04. | BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory | 182 | GlobeNewswire (Europe) | KUALA LUMPUR, Malaysia, April 15, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company"), a diversified biotechnology and specialty materials group headquartered... ► Artikel lesen | |
| 15.04. | BioNexus Gene Lab Corp - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.04. | BioNexus Gene Lab Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 03.04. | BioNexus Gene Lab announces reverse stock split | 1 | Investing.com | ||
| 03.04. | BioNexus Gene Lab Corp - 8-K, Current Report | 3 | SEC Filings | ||
| 25.03. | BioNexus Gene Lab Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 07.03. | Krypto-Revolution: BioNexus schreibt Geschichte: Ethereum triumphiert über Bitcoin! | 4.672 | wallstreetONLINE | © Foto: Jakub Porzycki - NurPhotoBioNexus setzt als erstes Nasdaq-Unternehmen auf Ethereum statt Bitcoin und wagt trotz finanzieller Herausforderungen einen kühnen Schritt in die Krypto-Zukunft.Die... ► Artikel lesen | |
| 06.03. | Krypto-Revolution: Ethereum statt Bitcoin: Nasdaq-Unternehmen BioNexus schreibt Krypto-Geschichte! | 1.047 | wallstreetONLINE | © Foto: Jakub Porzycki - NurPhotoBioNexus setzt als erstes Nasdaq-Unternehmen auf Ethereum statt Bitcoin und wagt trotz finanzieller Herausforderungen einen kühnen Schritt in die Krypto-Zukunft.Die... ► Artikel lesen | |
| 06.03. | BioNexus Stock Pops As It Embraces Ethereum-Focused Treasury Strategy, Says It Is First On Nasdaq To Do So | 5 | Benzinga.com | ||
| 05.03. | BioNexus Gene Lab adopts Ethereum for treasury strategy | 4 | Investing.com |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DRAEGERWERK | 66,20 | -1,05 % | Draegerwerk AG & Co. KGaA: Dräger bestätigt Q2-Trends und starker Auftragseingang unterstützt Visibilität. HALTEN. | Dräger bestätigt die Ergebnisse für das 2. Quartal 2025 mit einem Umsatzanstieg von 1,8% (wb.) auf 780 Mio EUR und einem EBIT von 20 Mio EUR, was den Wegfall von Einmalerträgen aus dem Vorjahr widerspiegelt.... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,115 | +6,48 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes | LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics ("Sernova") (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,648 | -0,77 % | RedChip Companies, Inc.: NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FL / ACCESS Newswire / August 29, 2025 / RedChip Companies will air interviews with NioCorp Developments Ltd. (Nasdaq:NB) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip Small Stocks... ► Artikel lesen | |
| PING AN HEALTHCARE | 2,352 | +2,22 % | PA GOODDOCTOR (01833): 2025 INTERIM REPORT | ||
| SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced | BOULDER, CO / ACCESS Newswire / August 26, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,000 | 0,00 % | Mountain Valley MD Holdings Inc: Mountain Valley appoints Batchelor as director | ||
| CO-DIAGNOSTICS | 0,270 | +3,85 % | Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results | SALT LAKE CITY, Aug. 14, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development... ► Artikel lesen | |
| CYTOSORBENTS | 0,793 | -2,46 % | CytoSorbents Corporation: CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR | FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization... ► Artikel lesen | |
| VERU | 3,250 | -3,56 % | VERU INC. - 8-K, Current Report | ||
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update | Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines... ► Artikel lesen | |
| VOLITIONRX | 0,689 | +0,85 % | VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for Friday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Aug. 14, 2025 /PRNewswire/ -- VolitionRx... ► Artikel lesen | |
| EKSO BIONICS | 3,870 | 0,00 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Second Quarter 2025 Financial Results | SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
| IMUNON | 5,230 | +2,55 % | Imunon, Inc.: IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement | LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company... ► Artikel lesen | |
| BEYOND AIR | 2,220 | +1,83 % | Beyond Air Signs New International LungFit PH Distribution Agreements, Most Notably in Japan | GARDEN CITY, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| AVINGER | 0,465 | -22,17 % | NSE - Avinger Inc - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities |
BIONEXUS GENE LAB CORP gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 5,720 Euro und damit -0,87 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIONEXUS GENE LAB CORP finden Sie auf Wallstreet Online.